Monopar Therapeutics operates as a biopharmaceutical company focused on the development of innovative therapies for rare and orphan diseases. The company specializes in creating treatments that address unmet medical needs, particularly in areas where existing therapies are limited or non-existent. Monopar Therapeutics leverages its expertise in drug development to advance its pipeline of therapeutic candidates, aiming to improve patient outcomes through targeted and effective treatments. The company generates revenue through the development and...
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | VRTX | Vertex Pharmaceuticals Inc / Ma | 109.90 Bn | 27.78 | 9.16 | - |
| 2 | REGN | Regeneron Pharmaceuticals, Inc. | 76.53 Bn | 16.96 | 5.34 | 1.99 Bn |
| 3 | ALNY | Alnylam Pharmaceuticals, Inc. | 39.60 Bn | 143.93 | 12.57 | - |
| 4 | RVMD | Revolution Medicines, Inc. | 27.52 Bn | -24.37 | 33,158.07 | - |
| 5 | ZLAB | Zai Lab Ltd | 24.25 Bn | -138.37 | 100.02 | 0.20 Bn |
| 6 | MESO | Mesoblast Ltd | 22.87 Bn | -179.20 | 1,330.04 | 0.12 Bn |
| 7 | RPRX | Royalty Pharma plc | 21.29 Bn | 27.68 | 8.95 | 8.95 Bn |
| 8 | ROIV | Roivant Sciences Ltd. | 19.34 Bn | -31.53 | 3,368.96 | - |